Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a new discovery project for a cancer indication, a liver targeted nucleotide prodrug for the treatment of hepatocellular carcinoma (HCC). The project is based on the company’s expertise in nucleoside and nucleotide science and is the first cancer project to emerge from its in-house discovery efforts in oncology that were announced in 2014.
“Our HCC nucleotide project has made very rapid progress after its initiation last year” said Richard Bethell, EVP Discovery Research. “We have identified molecules with excellent activity against a range of HCC cell lines and with the required distribution properties to enable them to be delivered selectively to the liver. Preclinical testing of these molecules in relevant models of HCC will begin early in the third quarter.”
Hepatocellular carcinoma is the most common cancer of the liver. Liver cancer is the second leading cause of cancer-related death world-wide, and one of the fastest growing cancers in the US based on incidence and mortality.
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Richard Bethell, EVP Discovery Research Medivir AB, mobile: +46 (0) 727 043 211
Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 08.30 CET on 30 June 2015.
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.